Neuren Pharmaceuticals Limited (OTCMKTS:NURPF) Sees Significant Growth in Short Interest

Neuren Pharmaceuticals Limited (OTCMKTS:NURPF) saw a large growth in short interest in the month of August. As of August 14th, there was short interest totaling 66,541 shares, a growth of 301.8% from the July 30th total of 16,560 shares. Based on an average daily volume of 1,169 shares, the short-interest ratio is currently 56.9 days.

Neuren Pharmaceuticals Price Performance

OTCMKTS NURPF opened at C$16.24 on Friday. The company has a 50 day simple moving average of C$13.70 and a 200-day simple moving average of C$10.48. Neuren Pharmaceuticals has a 52-week low of C$7.70 and a 52-week high of C$17.25.

Neuren Pharmaceuticals Company Profile

Neuren Pharmaceuticals (OTCMKTS:NURPF) is an Australian-based clinical-stage biopharmaceutical company focused on developing innovative peptide-based therapeutics for the treatment of neurodevelopmental and neurodegenerative disorders. The company’s research efforts center on addressing unmet medical needs in conditions such as Rett syndrome, Fragile X syndrome and Angelman syndrome. Neuren is publicly traded on the Australian Securities Exchange and maintains an over-the-counter listing in the United States, reflecting its commitment to global capital markets and investor engagement.

The company’s lead candidate, trofinetide (NNZ-2566), is a synthetic analogue of a naturally occurring peptide that has been evaluated in late-stage clinical trials for Rett syndrome and Fragile X syndrome.